We are well-positioned to grow via key market
opportunities at the forefront of global healthcare, including the
incoming U.S. administration's aim to "Make America Healthy Again"
by tackling chronic disease.
- Commercial and Community Care-Delivery: Continued expansion
with market-leading employer, provider and payvider innovation
partners
- Growth of GLP-1s: Engagement expertise provides unique
ability to facilitate sustainable health outcomes and
demonstrable ROI to GLP-1 sponsors
- Rise of Health AI: Unique data sets and capabilities will
enrich and accelerate progress of next-gen clinical discovery
platforms
TORONTO, Nov. 27,
2024 /CNW/ - Newtopia Inc. ("Newtopia" or the
"Company") (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole
health platform creating sustainable habits that prevent, slow and
reverse chronic disease, today announced its third quarter 2024
financial results, operational highlights and filing of its
financial statements. These results pertain to the three months
ended September 30, 2024. All amounts
are expressed in Canadian dollars, unless otherwise noted.
Third Quarter 2024 Financial Highlights:
- Revenue of $1.0 million
- Opex reduction of 16%
- New partnership with US supplemental payvider positions
Newtopia for profitability in 2025
"As we have for eleven years, Newtopia continues to prove our
unique ability to produce industry-leading patient engagement and
to cultivate healthy habits that can prevent, slow and reverse
chronic metabolic disease", said Jeff
Ruby, Newtopia Founder and CEO. "Most recently, we reported
nine-month outcomes from our ongoing trial with Arkansas-based Heartland Whole Health
Institute, in which we delivered Newtopia's best-ever
engagement rates and weight loss outcomes in both provider and
employer environments."
"This quarter we also further strengthened our underlying
operations, and evolved our offerings to respond to emerging
industry opportunities and value-based needs, including the
incoming US administration's desire to 'Make America Healthy Again'
by tackling chronic disease – something we do better than anyone
else in the market", continued Ruby.
"Building on the strength of this progress we continue to pursue
three significant opportunities to accelerate Newtopia growth in
the final quarter of the year and into 2025: (1) expanding our key
innovation partnerships with providers, employers and provincial
payers, including a new relationship with a US Supplemental
Payvider covering millions of employee lives; (2) combining
Newtopia's proven habit change platform with GLP-1 drugs for
obesity and type 2 diabetes; and (3) partnering with health AI and
clinical discovery innovators to improve our collective ability to
deliver best in breed outcomes that prevent, reverse and slow
chronic disease", Ruby concluded.
Third Quarter 2024 Financial Results
Revenue for the three months ended September 30, 2024 was $1.0 million compared to $2.4 million in the prior-year period. This
decrease is driven by the loss of a client effective June 2024, in addition to a structural incentive
change with an existing client which the Company is actively
working to offset. Gross profit for the third quarter was
$0.3 million, or 34% of revenue.
Gross profit consists of revenue less direct expenses, including
the cost of Welcome Kits and labor costs associated with the
Company's frontline health coaching team.
Adjusted operating expenses for the three months ended
September 30, 2024, totaled
$1.3 million, compared to
$1.6 million in the prior-year
period. The Company posted an adjusted operating loss of
$987 thousand, compared to a gain of
$21 thousand in the prior-year
period. Given the new partnership with a US payvider, Newtopia
anticipates returning to profitable growth in the near future.
Conference Call
The Company will host a conference call November 27 at 5 p.m.
eastern time to discuss the third quarter 2024 results in
further detail. To access the conference call, please dial (800)
717-1738 (U.S.) or (646) 307-1865 (International) 10 minutes prior
to the start time and reference Conference ID number 15026. The
call will also be available via live webcast on the investor
relations portion of the Company's website located at
investor.newtopia.com.
A replay of the conference call will be available through
December 18, 2024, which can be
accessed by dialing (844) 512-2921 (U.S.) or (412) 317-6671
(International) and entering the passcode 11157569. The webcast
will also be archived on the Company's website.
About Newtopia
Newtopia is a personalized whole health platform helping people
create positive lifelong habits that prevent, slow, or reverse
chronic disease while reducing healthcare costs. The platform
leverages genetic, social and behavioral insights to create
individualized prevention programs with a focus on metabolic
disease, diabetes, mental health challenges, hypertension, weight
management and musculoskeletal disorders. With a person-centered
approach that combines virtual care, digital tools, connected
devices and actionable data science, Newtopia delivers sustainable
clinical and financial outcomes. Newtopia serves some of the
largest nationwide employers and health plans and is currently
listed in Canada on the Toronto
Stock Exchange (TSXV: NEWU) and is quoted in the US on the
OTCQB® Venture Market (OTCQB: NEWUF). To learn
more, visit newtopia.com, LinkedIn or X.
Forward Looking Statements
This news release contains forward-looking information and
forward-looking statements, within the meaning of applicable
Canadian securities legislation, and forward looking statements,
within the meaning of applicable United
States securities legislation (collectively,
"forward-looking statements"), which reflects management's
expectations regarding Newtopia's future growth, results from
operations (including, without limitation, future production and
capital expenditures), performance (both operational and financial)
and business prospects and opportunities. Wherever possible, words
such as "predicts", "projects", "targets", "plans", "expects",
"does not expect", "budget", "scheduled", "estimates", "forecasts",
"anticipate" or "does not anticipate", "believe", "intend" and
similar expressions or statements that certain actions, events or
results "may", "could", "would", "might" or "will" be taken, occur
or be achieved, or the negative or grammatical variation thereof or
other variations thereof, or comparable terminology have been used
to identify forward-looking statements. All statements other than
statements of historical fact may be forward- looking information.
Such statements reflect Newtopia's current views and intentions
with respect to future events, based on information available to
Newtopia, and are subject to certain risks, uncertainties, and
assumptions. Material factors or assumptions were applied in
providing forward-looking information. While forward-looking
statements are based on data, assumptions and analyses that
Newtopia believes are reasonable under the circumstances, whether
actual results, performance or developments will meet Newtopia's
expectations and predictions depends on a number of risks and
uncertainties that could cause the actual results, performance and
financial condition of Newtopia to differ materially from its
expectations. Forward-looking statements are not a guarantee and
are based on a number of estimates and assumptions management
believes to be relevant and reasonable, whether actual results,
performance or developments will meet Newtopia's expectations and
predictions depends on a number of risks and uncertainties that
could cause the actual results, performance and financial condition
of Newtopia to differ materially from its expectations. Certain of
the "risk factors" that could cause actual results to differ
materially from Newtopia's forward-looking statements in this press
release include, without limitation: the termination of contracts
by clients, risks related to COVID-19 including various
recommendations, orders and measures of governmental authorities to
try to limit the pandemic, including travel restrictions, border
closures, non-essential business closures, quarantines,
self-isolations, shelters- in-place and social distancing,
disruptions to markets, economic activity, financing, supply chains
and sales channels, and a deterioration of general economic
conditions including a possible national or global recession; and
other general economic, market and business conditions and factors,
including the risk factors discussed or referred to in Newtopia's
disclosure documents, filed with the securities regulatory
authorities in certain provinces of Canada and available at www.sedarplus.ca
including Newtopia's final long form prospectus dated March 30, 2020.
For more information on these risks please see the "Risk
Factors" in Newtopia's final long-form prospectus dated
March 30, 2020. Should any factor
affect Newtopia in an unexpected manner, or should assumptions
underlying the forward-looking information prove incorrect, the
actual results or events may differ materially from the results or
events predicted. Any such forward-looking information is expressly
qualified in its entirety by this cautionary statement. Moreover,
Newtopia does not assume responsibility for the accuracy or
completeness of such forward-looking information. The
forward-looking information included in this news release is made
as of the date of this news release, and Newtopia undertakes no
obligation to publicly update or revise any forward-looking
information, other than as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Key Financial Measures and Schedule of Non-GAAP
Reconciliations
Unaudited Gross Profit Information-
including amortization
|
Three Months Ended
September 30,
|
|
Nine Months Ended
September 30,
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
|
$
|
|
$
|
|
$
|
|
$
|
Revenue
|
986,116
|
|
2,434,606
|
|
4,369,086
|
|
7,440,297
|
Cost of
revenue
|
(651,969)
|
|
(1,040,988)
|
|
(2,359,758)
|
|
(3,501,663)
|
Gross profit
|
334,147
|
|
1,393,618
|
|
2,009,328
|
|
3,938,634
|
|
|
|
|
|
|
|
|
Gross profit
margin
|
34 %
|
|
57 %
|
|
46 %
|
|
53 %
|
Reconciliation of Total Operating Expenses to Adjusted
Operating Expenses
|
Three Months Ended September
30,
|
|
Nine Months Ended September 30,
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
|
$
|
|
$
|
|
$
|
|
$
|
Total
expenses
|
1,978,493
|
|
2,164,039
|
|
6,038,822
|
|
7,313,195
|
Add
(Subtract)
|
|
|
|
|
|
|
|
Share-based
compensation
|
(54,851)
|
|
(158,584)
|
|
(195,941)
|
|
(466,887)
|
Depreciation of
property and equipment
|
(483)
|
|
(1,386)
|
|
(1,953)
|
|
(4,965)
|
Debenture
interest and accretion expense
|
(300,997)
|
|
(246,556)
|
|
(844,321)
|
|
(593,979)
|
Interest on
promissory note
|
(2,000)
|
|
-
|
|
(2,000)
|
|
-
|
Interest on
lease obligations
|
-
|
|
(5,221)
|
|
-
|
|
(26,784)
|
Finance
charges
|
(256,482)
|
|
(145,024)
|
|
(496,171)
|
|
(376,990)
|
Amortization of
deferred finance charges
|
(44,984)
|
|
(39,710)
|
|
(130,884)
|
|
(107,500)
|
Foreign exchange
gain (loss)
|
2,094
|
|
17,302
|
|
32,843
|
|
(36,791)
|
(Loss) Gain on
settlement of related party payable
|
-
|
|
3,111
|
|
(9,797)
|
|
10,314
|
|
|
|
|
|
|
|
|
Adjusted operating
expenses
|
1,320,790
|
|
1,579,015
|
|
4,390,598
|
|
5,700,657
|
Unaudited Adjusted Operating Loss
|
Three Months Ended Sep
30,
|
|
Nine Months Ended Sep
30,
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
|
$
|
|
$
|
|
$
|
|
$
|
Gross profit
|
334,147
|
|
1,393,618
|
|
2,009,328
|
|
3,938,634
|
Add back amortization
of intangible asset
|
-
|
|
206,509
|
|
-
|
|
619,537
|
Adjusted gross
profit
|
334,147
|
|
1,600,127
|
|
2,009,328
|
|
4,558,171
|
Adjusted operating
expenses
|
(1,320,790)
|
|
(1,579,015)
|
|
(4,390,598)
|
|
(5,700,657)
|
Adjusted operating
loss
|
(986,643)
|
|
21,112
|
|
(2,381,270)
|
|
(1,142,486)
|
Newtopia Inc.
Condensed Interim Consolidated
Statements of Financial Position (Unaudited)
As at
September 30, 2024 and December 31, 2023
(Expressed in
Canadian Dollars)
|
|
September
30,
|
|
December
31,
|
|
|
|
2024
|
|
2023
|
|
|
|
$
|
|
$
|
|
Assets
|
|
|
|
|
Current
assets
|
|
|
|
|
|
Cash
|
10,200
|
|
387,339
|
|
|
Trade and other
receivables
|
381,061
|
|
1,400,959
|
|
|
Contract
assets
|
-
|
|
259,072
|
|
|
Prepaid expenses and
deposits
|
137,226
|
|
101,043
|
|
|
Inventories
|
91,654
|
|
115,232
|
|
|
Deferred
costs
|
41,979
|
|
64,583
|
|
|
|
|
|
|
|
|
|
662,120
|
|
2,328,228
|
|
|
|
|
|
|
|
|
Property and
equipment
|
2,712
|
|
4,665
|
|
|
|
|
|
|
|
|
|
664,832
|
|
2,332,893
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
Trade and other
payables
|
2,415,716
|
|
1,825,356
|
|
|
Credit
facility
|
4,865,674
|
|
4,767,006
|
|
|
Promissory
note
|
200,000
|
|
-
|
|
|
Contract
Liability
|
48,746
|
|
-
|
|
|
Deferred
revenue
|
-
|
|
48,185
|
|
|
Debentures
|
5,735,672
|
|
3,723,530
|
|
|
|
13,265,808
|
|
10,364,077
|
|
|
|
|
|
|
|
|
Debentures
|
-
|
|
1,387,476
|
|
|
|
13,265,808
|
|
11,751,553
|
|
|
|
|
|
|
|
Shareholders' Equity
(Deficit)
|
|
|
|
|
|
Common
shares
|
49,754,858
|
|
49,404,596
|
|
|
Contributed
surplus
|
14,648,104
|
|
14,151,188
|
|
|
Deficit
|
(77,003,938)
|
|
(72,974,444)
|
|
|
|
(12,600,976)
|
|
(9,418,660)
|
|
|
|
664,832
|
|
2,332,893
|
|
Newtopia Inc.
Condensed Interim Consolidated
Statements of Loss and Comprehensive Loss (Unaudited)
Three Months Ended September 30,
2024
(Expressed in Canadian Dollars)
|
|
2024
|
2023
|
|
|
|
$
|
$
|
|
Revenue
|
986,116
|
2,434,606
|
|
Cost revenue
|
|
651,969
|
1,040,988
|
|
Gross
profit
|
|
334,147
|
1,393,618
|
|
|
|
|
|
|
Operating
expenses
|
|
|
|
Technology and
development
|
366,732
|
446,504
|
|
Sales and
marketing
|
163,261
|
317,544
|
|
General and
administrative
|
790,797
|
814,967
|
|
Share-based
compensation
|
54,851
|
158,584
|
|
Depreciation of
property and equipment
|
|
483
|
1,386
|
|
|
|
1,376,124
|
1,738,985
|
|
Other expenses
(income)
|
|
|
|
Interest on
lease obligations
|
-
|
5,221
|
|
Debenture
interest and accretion expense
|
300,997
|
246,556
|
|
Interest on
promissory note
|
2,000
|
-
|
|
Finance
charges
|
256,482
|
145,024
|
|
Foreign exchange
(gain) loss
|
(2,094)
|
(17,302)
|
|
(Gain) Loss on
settlement of related party payable
|
-
|
(3,111)
|
|
Amortization of
deferred finance charges
|
44,984
|
39,710
|
|
|
|
|
|
|
|
|
602,369
|
425,054
|
|
|
|
|
|
|
Net loss and
comprehensive loss
|
(1,644,346)
|
(770,421)
|
|
|
|
|
|
|
|
Loss per
share
|
|
|
|
Basic and
diluted loss per share
|
(0.01)
|
(0.01)
|
|
|
|
|
|
|
Weighted average
number of shares outstanding
|
|
|
|
Basic and
diluted
|
173,265,303
|
153,829,313
|
|
Newtopia Inc.
Condensed Interim Statements of Cash
Flows (Unaudited)
Nine Months Ended September 30, 2024
(Expressed in
Canadian Dollars)
|
|
|
2024
|
2023
|
|
|
|
$
|
$
|
Cash flows used in
operating activities
|
|
|
|
Net loss and
comprehensive loss
|
(4,029,494)
|
(3,374,561)
|
|
Items not involving
cash
|
|
|
|
|
Depreciation of
property and equipment
|
1,953
|
4,965
|
|
|
Amortization of
intangible asset
|
-
|
619,537
|
|
|
Amortization of
deferred finance charge
|
130,884
|
107,500
|
|
|
Debenture interest and
accretion expense
|
624,661
|
353,530
|
|
|
Interest on promissory
note
|
2,000
|
-
|
|
|
Interest on lease
obligations
|
-
|
26,784
|
|
|
Debt
modification
|
-
|
8,956
|
|
|
Credit facility
interest
|
130,466
|
-
|
|
|
Share-based
compensation
|
195,941
|
466,887
|
|
|
(Gain) Loss on
settlement of related party payable
|
9,797
|
(10,314)
|
|
|
|
(2,933,792)
|
(1,796,716)
|
|
Change in non-cash
working capital
|
|
|
|
|
Trade and other
receivables
|
1,019,898
|
(216,987)
|
|
|
Prepaid expenses and
deposits
|
(36,183)
|
(33,712)
|
|
|
Inventories
|
23,578
|
208,151
|
|
|
Trade and other
payables
|
442,895
|
(502,016)
|
|
|
Deferred
revenue
|
(48,185)
|
-
|
|
|
Contract
asset/liability
|
307,818
|
174,670
|
|
|
|
(1,223,971)
|
(2,166,610)
|
Cash flows used in
investing activities
|
|
|
|
|
Purchase of property
and equipment
|
-
|
(2,548)
|
|
|
|
-
|
(2,548)
|
Cash flows from
financing activities
|
|
|
|
|
Credit facility
withdrawals
|
(3,726,407)
|
4,706,984
|
|
|
Credit facility
repayments
|
3,825,080
|
(5,167,679)
|
|
|
Credit facility
financing costs
|
(93,280)
|
(117,260)
|
|
|
Promissory
note
|
200,000
|
-
|
|
|
Repayment of lease
obligation
|
-
|
(464,998)
|
|
|
Proceeds from private
placement issuance of Units, net of costs
|
641,440
|
1,467,295
|
|
|
Proceeds from issuance
of debenture units, net of costs
|
-
|
1,746,201
|
|
|
Repayment of
debentures
|
-
|
(30,000)
|
|
|
proceeds from exercise
of warrants
|
-
|
258,299
|
|
|
|
|
|
|
|
|
846,833
|
2,398,842
|
(Decrease) Increase in
cash
|
(377,139)
|
229,684
|
Cash, beginning of
period
|
387,339
|
345,950
|
Cash, end of
period
|
10,200
|
575,634
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/newtopia-reports-third-quarter-2024-financial-results-302317816.html
SOURCE Newtopia Inc.